The pharmaceutical industry has weighed in on President Barack Obama’s proposed 2014 fiscal year budget, finding much to criticize, including a provision that would prohibit the owners of prescription drug patents from entering settlement agreements with generic competitors paying to delay the generic’s entry into the market in return for the dismissal of patent invalidity litigation. Other budget proposals would reduce the exclusivity period of biologic medicines from 12 to seven years and prevent biologics “evergreening,” that is, extending patent protection by taking out new patents for altered delivery systems or new mixtures of patented drugs. The Pharmaceutical Research and Manufacturers of America (PhRMA) called the proposal “bad for patients, bad for innovation and bad for the economy.” While the president’s budget is not expected to be enacted, it does establish a number of bargaining positions for the congressional negotiations to come. See PhRMA Press Statement, April 10, 2013.